Loading
SHR-8068 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for biliary tract cancer, non-small-cell lung cancer and cervical cancer, with its target not yet stated publicly.
SHR-8068 is an investigational agent whose form is not stated in the registry developed by Suzhou Suncadia Biopharmaceuticals and Shanghai Hengrui Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip. It is the investigational product in 10 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07229625 (A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)), in biliary tract cancer, non-small-cell lung cancer, cervical cancer, gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer. The largest, NCT06703177, plans to enrol 876 participants with primary completion was scheduled for 2026-01-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.SHR-8068 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SHR-8068" OR ABSTRACT:"SHR-8068") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SHR-8068, not a curated reading list.
Shares A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma, A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Jiangsu Hengrui Pharmaceuticals, Cervical cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Cervical cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Cervical cancer, Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer, Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.